
|Videos|October 19, 2015
Optimizing the Specialty Drug Pathway from Manufacturers to Pharmacies
Author(s)Davy James, Managing Editor
Cheryl Allen, RPh, BSPharm, MBA, vice president of Industry Relations at Diplomat, discusses how relationships can be improved between manufacturers, pharmacy benefit managers, and pharmacies.
Advertisement
Cheryl Allen, RPh, BSPharm, MBA, vice president of Industry Relations at Diplomat, discusses how relationships can be improved between manufacturers, pharmacy benefit managers, and pharmacies.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves First At-Home Treatment Device for Depression
2
Emerging Data from the DESTINY-Breast Trials Signal Shift in Standards of Care for HER2-Positive Breast Cancer
3
ADCs in Breast Cancer: Shaping the Future of HER2– and TROP-2–Targeted Therapy
4
FDA Approves Gepotidacin for Urogenital Gonorrhea in Adult and Pediatric Patients
5

















































































































































































































